BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Imaging and targeting premetastatic niches and immune modulators i
 n melanoma
DTSTART:20201029T121500
DTEND:20201029T133000
DTSTAMP:20260609T230403Z
UID:4c9c2233615ed0ad32ccd5171f90d830706f0f4cf20473231d23ee52
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Marisol SOENGAS Melanoma Group    Centro Nacional de In
 vestigaciones Oncológicas - CNIO - Madrid - Spain\n \nA Lola and John Gr
 ace Distinguished Lecture in Cancer Research\nThis seminar will also be te
 levised to AGORA Auditorium Paternot + Biopôle B301/CLE + Geneva Universi
 ty TBC\n\nMaría S. (Marisol) Soengas is the Head of the Melanoma Group an
 d the Dean for Academic Affairs at the Spanish National Cancer Research Ce
 ntre (CNIO) in Madrid. The long-term goal of her team is to translate basi
 c research in melanoma into the clinic by identifying novel tumour markers
  and drug targets. The interest of Soengas for melanoma stemmed from her s
 tudies as a postdoctoral fellow at Cold Spring Harbor Laboratory (NY). The
 re\, she performed the first functional characterization of apoptotic fact
 ors as melanoma suppressors and chemoresistance mediators. She then decide
 d to incorporate patient biopsies to her projects on cellular and animal m
 odels of melanoma. To this end\, she joined the Department of Dermatology 
 at the University of Michigan\, which hosts one of the largest Multidiscip
 linary Melanoma Clinics in the US. As an Assistant Professor\, her group f
 urther defined novel roles of additional stress response programs (involvi
 ng autophagy\, senescence and endosome mobilization). In 2008 she moved to
  the CNIO\, setting up a multidisciplinary laboratory which has now expand
 ed to ambitious national and international networks. Examples of recent di
 scoveries of her group are the identification of a cluster of endolysosoma
 l factors that are selectively enriched in melanoma and distinguish this d
 isease from over 35 tumor types. Non-invasive imaging of pre-metastatic ni
 ches is also being developed by her team as a cost-effective platform for 
 drug screening and pharmacokinetic analyses. To facilitate the transfer of
  knowledge from the bench to the bedside\, Soengas cofounded Bioncotech Th
 erapeutics\, a spin off of the CNIO involved in the clinical development o
 f proprietary dsRNA-based nanocomplexes of her group. Soengas participates
  in multiple review panels\, and is member of the editorial boards of vari
 ous journals. She has received fellowships and awards from the Human Front
 iers in Science Program\, the Leukemia and Lymphoma Society of America\, t
 he American Dermatology Foundation\, the Elsa V. Pardee Foundation\, the V
  Foundation for Cancer Research. She also received the Dana Ashby Young In
 vestigator Award of the Society for Melanoma Research\, and is a Team Scie
 nce Project Leader of the Melanoma Research Alliance
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717
STATUS:CANCELLED
END:VEVENT
END:VCALENDAR